Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
Go back to Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients| Edwards Lifesciences (NYSE: EW) | Delayed: 86.72 -3.18 (3.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $89.90 | 52 Week High | $166.87 | |||
| Open | $89.07 | 52 Week Low | $72.20 | |||
| Day High | $89.10 | P/E | 25.21 | |||
| Day Low | $86.39 | EPS | $3.44 | |||
| Volume | 3,583,987 | |||||
